European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling